CONDITIONS WE TREAT
Persistent Lyme disease and tick-borne co-infections represent a complex biological challenge — Borrelia burgdorferi's ability to evade immune detection, persist in protected tissue compartments, and drive chronic inflammation requires a multi-system approach. SynergyO3 targets the biological mechanisms sustaining symptoms after initial treatment.
CLINICAL PRESENTATION
Lyme disease and co-infections (Bartonella, Babesia, Ehrlichia, Anaplasma) produce symptom patterns that overlap with many other chronic conditions. Persistent or late-stage Lyme requires comprehensive biological evaluation beyond standard antibody testing. Individual results vary.
SynergyO3 works with patients managing persistent Lyme disease (Post-Treatment Lyme Disease Syndrome), Bartonella, Babesia, Ehrlichia, and patients with complex multi-system illness following tick exposure — including those with negative conventional serology who carry strong clinical presentations.
Testing may include Igenex or Galaxy Diagnostics tick-borne panels, CD57 NK cell counts (marker of chronic Lyme immune suppression), C4a and TGF-β1 (biotoxin inflammation markers), comprehensive coinfection serology, and cytokine panels showing persistent immune activation patterns.
COMMONLY OVERLAPPING CONDITIONS
CLINICAL EDUCATION
Borrelia burgdorferi is a highly evolved pathogen capable of immune evasion through multiple mechanisms: forming protective biofilms, adopting intracellular locations, persisting in collagen-rich tissues, and suppressing NK cell activity. Chronic Lyme involves a combination of persistent infection burden, immune dysregulation, and secondary neuroinflammation.
Borrelia forms protective biofilm communities that physically shield bacteria from antibiotics and immune cells. Persister cells within biofilms are metabolically dormant and highly resistant to conventional antibiotic treatment, enabling Borrelia to survive standard courses of therapy.
Borrelia actively suppresses natural killer (NK) cell activity, particularly CD57+ NK cells that serve as markers of chronic immune suppression. Low CD57 counts (<60) correlate with persistent disease burden and are used clinically to track response to treatment.
Borrelia and its co-infections cross the blood-brain barrier and activate microglial cells, generating pro-inflammatory cytokines that drive neurological symptoms. Persistent neuroinflammation may continue even when active infection burden is reduced, requiring targeted anti-inflammatory support.
KEY STATISTICS
Comprehensive intake, targeted labs, and biomarker assessment to map biological drivers.
Physician-designed sequenced protocol combining EBOO, HOCATT, and IV nutrients.
Follow-up labs, functional benchmarks, and protocol refinement based on response.
ROOT CAUSE INVESTIGATION
Dr. Volpp evaluates each patient's complete picture — identifying which biological mechanisms are most active — before any protocol is designed. Individual results vary.
Even when Borrelia burden is reduced, dysregulated immune activation and cytokine storms continue driving symptoms. TNF-α, IL-6, and IL-8 remain elevated in many persistent Lyme patients, suggesting immune dysregulation independent of active infection burden.
Borrelia and its toxins impair mitochondrial function, reducing cellular ATP production and driving the profound fatigue characteristic of persistent Lyme. Oxidative damage to mitochondria compounds the energy deficit, creating a recovery barrier that antimicrobials alone cannot address.
Chronic Lyme generates significant oxidative stress that damages neurological tissues, depletes antioxidant reserves, and creates ongoing cellular injury. Reducing this oxidative burden is a critical component of neurological symptom recovery in persistent Lyme patients.
TREATMENT APPROACH
All protocols are physician-designed and supervised by Dr. Heather Volpp, MD. Therapies are selected based on each patient's evaluation. Results may vary.
EBOO ozone therapy has direct antimicrobial properties and may help address the oxidative and immune components of persistent Lyme — including biofilm disruption support, immune modulation, mitochondrial restoration, and reduction of the neuroinflammatory burden driving ongoing symptoms.
The HOCATT's ozone steam, far-infrared, and carbonic acid combination may support lymphatic clearance of Borrelia toxins, reduce joint and tissue inflammation, and support autonomic nervous system rebalancing in Lyme patients.
YOUR PATH FORWARD
Every patient begins with a comprehensive physician evaluation. No protocol begins before Dr. Volpp has reviewed your complete clinical picture.
A comprehensive intake with Dr. Volpp reviewing your symptom timeline, prior lab work, medications, and functional status. Targeted lab panels are ordered to identify active biological drivers.
Based on your evaluation findings, Dr. Volpp designs a sequenced treatment protocol — typically combining EBOO sessions, HOCATT therapy, and IV nutrient support at clinically appropriate intervals.
Functional benchmarks and symptom tracking guide protocol adjustments. Follow-up labs assess inflammatory markers and key biomarkers. Treatment frequency is adjusted as you progress toward your goals.
COMMON QUESTIONS
TAKE THE NEXT STEP
Begin with a comprehensive consultation with Dr. Heather Volpp, MD — Board-Certified Internal Medicine. Your evaluation will review your full clinical picture and identify which biological mechanisms may be driving your symptoms.
Book Your Appointment →Physician-Supervised · SynergyO3 Medical · Encinitas, CA · (760) 450-4602
Individual results vary. Consult with Dr. Volpp during your evaluation.
